XEGLYZE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xeglyze, and what generic alternatives are available?
Xeglyze is a drug marketed by Hatchtech and is included in one NDA. There are five patents protecting this drug.
This drug has thirty-six patent family members in fifteen countries.
The generic ingredient in XEGLYZE is abametapir. One supplier is listed for this compound. Additional details are available on the abametapir profile page.
DrugPatentWatch® Generic Entry Outlook for Xeglyze
Xeglyze was eligible for patent challenges on July 31, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 17, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XEGLYZE?
- What are the global sales for XEGLYZE?
- What is Average Wholesale Price for XEGLYZE?
Summary for XEGLYZE
International Patents: | 36 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 112 |
Patent Applications: | 283 |
What excipients (inactive ingredients) are in XEGLYZE? | XEGLYZE excipients list |
DailyMed Link: | XEGLYZE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XEGLYZE
Generic Entry Date for XEGLYZE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
LOTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for XEGLYZE
XEGLYZE is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of XEGLYZE is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting XEGLYZE
Pediculicidal composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions for controlling ectoparasites
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
FDA Regulatory Exclusivity protecting XEGLYZE
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XEGLYZE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Hatchtech | XEGLYZE | abametapir | LOTION;TOPICAL | 206966-001 | Jul 24, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XEGLYZE
When does loss-of-exclusivity occur for XEGLYZE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 14377875
Patent: Pediculicidal composition
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 33081
Patent: COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 1732
Patent: ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Patent: 1691033
Patent: ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 82424
Patent: COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 11751
Estimated Expiration: ⤷ Sign Up
Patent: 17500342
Patent: シラミ駆除組成物
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0995
Patent: Pediculicidal composition
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 67618
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering XEGLYZE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 2457582 | ⤷ Sign Up | |
New Zealand | 720995 | Pediculicidal composition | ⤷ Sign Up |
Hong Kong | 1169045 | 用於控制體外寄生蟲的方法和組合物 (METHOD AND COMPOSITIONS FOR CONTROLLING ECTOPARASITES) | ⤷ Sign Up |
China | 100593419 | ⤷ Sign Up | |
Canada | 2933081 | COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION) | ⤷ Sign Up |
European Patent Office | 2457582 | Procédé et compositions pour le contrôle d'ectoparasites (Method and compositions for controlling ectoparasites) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |